Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER2-Negative Breast Cancer
Interventions: DRUG: Pembrolizumab
Sponsor: University of Malaya
Collaborators: Merck Sharp & Dohme LLC|National University Hospital, Singapore|Cancer Research Malaysia